Several studies described the relationship between CPT-11 pharmacokinetic and clinical toxicity, including severe diarrhea and neutropenia. 6, 7 The UGT1A1*28 polymorphism, the most common allele, is associated with increase toxicity and leads to higher or more prolonged exposure of SN-38. [8] [9] [10] Furthermore, studies have shown that the area under curve (AUC) ratio SN-38G/SN-38 is clinically influencing factors in CPT-11-induced toxicity. 11, 12 Therapeutic drug monitoring (TDM) of CPT-11 and its metabolites are necessary to study with the interindividual variability in PK of CPT-11. 13 The purpose of this study was to develop and validate the LC-MS/MS for the simultaneous determination of CPT-11, SN-38, and SN-38G. This develop method was applied to study in pharmacokinetic parameters of CPT-11 and its metabolites in human plasma. 
| MATERIALS AND METHODS

| RESULTS
Method validation was performed using blank EDTA plasma. The eight-point standard curves were linear in the concentration range of 5-10 000 ng/mL for CPT-11, 5-1000 ng/mL for SN-38, and 8-1000 ng/mL for SN-38G. The average correlations of calibration curve were >0.9900. Quadratic regression with 1/x weighted concentrations was used to achieve homogeneity of variance. The signal to noise (S/N) was ≥5. The acceptable LLOQ of CPT-11, SN-38, and SN-38G was determined to be 5 ng/mL, 5 ng/mL, and 8 ng/mL, respectively and was validated through analysis of six replicates.
Accuracy, intraday and interday precision were determined by running six replicates of LLOQ and QC (QCL, QCM, QCH) samples on three different days. For US FDA guidance, these results demonstrated that the precision and accuracy values were in the acceptance range (<15%). In this assay, the intra and interday precision consisted of ≤9.11% and ≤11.29% for CPT-11, ≤8.70% and 8.31% for SN-38, and ≤9.90 and 9.64% for SN-38G.
The mean extraction recoveries were determined in six replicates at three QC concentrations. The recovery was in range 100.63- and SN-38G was 9.97±1.56, 11.93±5.13, and 13.90±2.37 hours, respectively (Table 1) .
| DISCUSSION
In this study, the LC-MS/MS method was successfully used to determine the CPT-11 and its metabolites in human plasma with a high accuracy and high precision. A 100-μL aliquot of the plasma samples, small-volume plasma, was performed by protein precipitation. 15 The process was used dry and reconstitute method to eliminate the organic solvent in protein precipitation. This LC-MS/MS method had a gradient process within 18 minutes that was faster than the method from Zhang et al. 16 with a gradient process in 30 minutes. The pharmacokinetic parameters of CPT-11 and its metabolites in this study had similar results to previous study. 17 The plasma AUC of SN-38 was 47-fold lower than CPT-11, whereas the AUC of SN-38G was sixfold higher than SN-38. The terminal elimination half-life of CPT-11 was 
| CONCLUSION
In this study, we developed and validated acceptable accuracy, precision, and extraction recovery with a good linearity according to the T A B L E 1 Pharmacokinetic parameters of CPT-11, SN-38, and SN-38G (n=4)
US FDA guidance on bioanalytical method validation. The method was successfully applied to a pharmacokinetic study of CPT-11 and its metabolites in human plasma. The further study, a pharmacokinetic study of CPT-11 and its metabolites should be studied in large sample size in Thai population with the consideration of UGT1A1 polymorphisms testing.
